There are 2949 resources available
279MO - Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
Presenter: Suzette Delaloge
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
537MO - First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
Presenter: Maria Vieito Villar
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA49 - Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
Presenter: Corinne Faivre-Finn
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1236MO - A single-arm phase II study of gefitinib with concurrent thoracic radiotherapy in unresectable locally-advanced non-small cell lung cancer patients with EGFR mutation (West Japan Oncology Group 6911L)
Presenter: Junichi Shimizu
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1237MO - SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Presenter: Sacha Rothschild
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA21 - Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
Presenter: Christophe Borg
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
400MO - Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial
Presenter: Lars Henrik Jensen
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
401MO - OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial
Presenter: Takayuki Yoshino
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
402MO - Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
Presenter: Sara Lonardi
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
403MO - Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
Presenter: Van Morris
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast